Cases & Deals

Jazz Pharmaceuticals acquires EUSA Pharma for $650 million

Clients Jazz Pharmaceuticals, Inc.

Jones Day acted as IP counsel in advising Jazz Pharmaceuticals, Inc. in connection with the execution of a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma for $650 million in cash and a potential $50 million milestone payable in cash based upon Erwinaze™ achieving a specified U.S. net sales target in 2013.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.